HB0056

HB0056 is a bispecific IgG1-type monoclonal antibody developed by Huaota Biopharmaceuticals (Shanghai Huaaotai Biopharmaceutical) that targets and inhibits both thymic stromal lymphopoietin (TSLP) and interleukin 11 (IL-11). By blocking these proteins, which are associated with immune and inflammatory responses, HB0056 aims to reduce inflammation in diseases such as moderate to severe asthma. The drug is currently in early clinical development, with Phase 1 trials underway to evaluate its safety, tolerability, pharmacokinetics, and immunogenicity in healthy adult volunteers. Its mechanism of action involves dual inhibition of TSLP and IL-11 signaling pathways[1][2][4][5].